Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

AST 487

HY-15002

(NVP-AST 487)

AST 487

AST 487 Chemical Structure

AST487(NVP-AST487) is a Ret kinase inhibitor/FLT3 inhibitor with IC50 of 0.88 uM for Ret.

Size Price Stock Quantity
10 mM * 1 mL in DMSO $297 In-stock
5 mg $255 In-stock
10 mg $460 In-stock
50 mg $925 In-stock
100 mg Get quote
200 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €291 In-stock
5 mg €250 In-stock
10 mg €451 In-stock
50 mg €907 In-stock
100 mg Get quote
200 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: AST 487
Cat. No.: HY-15002

AST 487 Data Sheet

  • View current batch:

    Purity: 99.35%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

Related Compound Libraries

Biological Activity of AST 487

AST487(NVP-AST487) is a Ret kinase inhibitor/FLT3 inhibitor with IC50 of 0.88 uM for Ret.
IC50 value: 0.88 uM
Target: Ret/FLT3
AST 487 displays high selectivity and potency toward FLT3 as a molecular target, and which could potentially be used to override drug resistance in AML. NVP-AST487 has an IC(50) of 0.88 mumol/L on RET kinase, inhibits RET autophosphorylation and activation of downstream effectors, and potently inhibited the growth of human thyroid cancer cell lines with activating mutations of RET but not of lines without RET mutations. NVP-AST487 induced a dose-dependent growth inhibition of xenografts of NIH3T3 cells expressing oncogenic RET, and of the MTC cell line TT in nude mice. NVP-AST487 inhibited calcitonin gene expression in vitro in TT cells, in part, through decreased gene transcription.

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 529.56 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C26H30F3N7O2
CAS No 630124-46-8
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.8884 mL 9.4418 mL 18.8836 mL
5 mM 0.3777 mL 1.8884 mL 3.7767 mL
10 mM 0.1888 mL 0.9442 mL 1.8884 mL

References on AST 487

Inhibitor Kit

Related FLT3 Products

  • AMG 925

    AMG 925 is a potent and selective dual inhibtor of CDK4/FLT3 with IC50s of 1.5 nM and 2.4 nM for CDK4 and FLT3, respectively; with IC50 of 19 nM in MOLM-13 cell.

  • Amuvatinib

    Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFR(alpha) and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively.

  • BPR1J-097

    BPR1J-097 is a novel small molecule FLT-3 inhibitor(IC50=11(plusmn)7 nM) with promising in vivo anti-tumour activities; inhibits FLT-3 D835Y with an IC50 of 3 nM.

  • FLT3-IN-1

    FLT3-IN-1 is a novel potent and selective Flt3 inhibitor with IC50 of 10 nM; against FLT3-ITD-expressing MV4-11 cells with IC50 of 6 nM.

  • FLT3-IN-2

    FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 (mu)M, detailed information refer to WO 2012158957 A2 and WO 2007013896.

  • G-749

    G-749 is a novel FLT3 inhibitor that showed potent and sustained inhibition of the FLT3 wild type and mutants with IC50s of 0.4/0.6/3.5/7.5 nM for Wt Flt3/D835Y/MV4-11/Molm-14 respectively.

  • Gilteritinib

    Gilteritinib(ASP-2215) is a potent FLT3/AXL inhibitor with IC50 of 0.29 nM/<1 nM respectively; shows potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.

  • KW-2449

    KW-2449 is a multiple-targeted inhibitor, mostly for Flt3 with IC50 of 6.6 nM, modestly potent to FGFR1, Bcr-Abl and Aurora A; little effect on PDGFR(beta), IGF-1R, EGFR.

  • Pacritinib

    Pacritinib (SB1518) is a potent and selective JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, respectively) and FLT3 (IC(50) = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50= 1280 and 520 nM, respectively).

  • Ponatinib

    Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFR(alpha), VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM, respectively.

MORE